Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 51 to 60 of 480 total matches.

In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
administration of the vaccine.1,2 In an April 14 emergency meeting, the Advisory Committee on Immunization ...
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1 | Show Introduction Hide Introduction

In Brief: New Adult Immunization Recommendations

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017  (Issue 1519)
Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available ...
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's website (www.cdc.gov/vaccines/schedule). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter.2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue.3DK Kim et al. Advisory Committee on Immunization Practices...
Med Lett Drugs Ther. 2017 Apr 24;59(1519):70 | Show Introduction Hide Introduction

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
a cephalosporin or a carbapenem with a beta-lactamase inhibitor such as ceftazidime/ avibactam (Avycaz),1 ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 | Show Introduction Hide Introduction

In Brief: An Asenapine Patch (Secuado) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
(PANSS) score at 6 weeks, the primary endpoint, than those who received placebo (see Table 1 ...
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since 2009.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):7-8 | Show Introduction Hide Introduction

Vonvendi - Recombinant von Willebrand Factor (online only)

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017  (Issue 1521)
(Stimate, and others; 1-deamino-8- D-arginine vasopressin, DDAVP) stimulates release of VWF and factor ...
The FDA has approved intravenously administered recombinant von Willebrand factor (Vonvendi - Shire) for adults with von Willebrand disease (VWD) who require on-demand treatment and control of bleeding episodes. It is the first recombinant von Willebrand factor (VWF) product to become available in the US.
Med Lett Drugs Ther. 2017 May 22;59(1521):e90-91 | Show Introduction Hide Introduction

Comparison Table: Some Topical Drugs for Rosacea (online only)

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017  (Issue 1521)
(Galderma) 1% cream Yes No Burning, irritation Fetal toxicity with very high doses in animals; no adequate ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2017 May 22;59(1521):e92 | Show Introduction Hide Introduction

Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
with extended-release metformin (Xigduo XR; Kombiglyze XR).1 Three SGLT2/DPP-4 inhibitor combinations are now ...
The FDA has approved Qtern (AstraZeneca), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) and the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (Onglyza), for oral treatment of adults with type 2 diabetes. Dapagliflozin and saxagliptin have each been available for years alone and in combination with extended-release metformin (Xigduo XR; Kombiglyze XR). Three SGLT2/DPP-4 inhibitor combinations are now available in the US (see Table 2).
Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-6 | Show Introduction Hide Introduction

Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018  (Issue 1554)
symptoms (COWS score ~11-12) Taper in decrements of 10-20% every 1-2 days; some patients, particularly ...
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Med Lett Drugs Ther. 2018 Aug 27;60(1554):e144-146 | Show Introduction Hide Introduction

ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
ZTlido — A New Lidocaine Patch for Postherpetic Neuralgia A lidocaine 1.8% patch (ZTlido – Scilex ...
A lidocaine 1.8% patch (ZTlido – Scilex) has been approved by the FDA for treatment of pain associated with postherpetic neuralgia (PHN). A lidocaine 5% patch (Lidoderm, and generics) was approved earlier for the same indication and has been used off-label for treatment of other types of localized pain. Both of these patches are available only by prescription. Lidocaine 4% patches (Aspercreme, IcyHot, and others) are available over the counter for back, neck, shoulder, and joint pain.
Med Lett Drugs Ther. 2019 Mar 25;61(1568):41-3 | Show Introduction Hide Introduction

In Brief: Tegaserod (Zelnorm) Returns

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
with tegaserod for 1-3 months, 13 (0.11%) had a confirmed ischemic event compared to only 1 (0.01%) of more than ...
Tegaserod maleate (Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults <65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic cardiovascular events (including...
Med Lett Drugs Ther. 2019 May 6;61(1571):72 | Show Introduction Hide Introduction